Review

HOW SHOULD BE THE SURGICAL APPROACH TO HER2 POSITIVE BREAST CANCER?

• Can Atalay

Importance of HER2/NEU (C-ERB-B2) Status in Breast Cancer: Which Method is More Effective to Evaluate of HER-2 Status?

• Nuket Eliyatkın
• Baha Zengel
• Safiye Aktaş

Original Article

Problems In Determining Her2 Status In Breast Carcinoma

• Emel Ebru Pala
• Ümit Bayol
• Alp Özgüzer
• Ülkü Küçük
• Çağlar Yıldız Akdeniz
• Özlem Sezer

Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report

• Umut Varol
• Burcu Çakar
• İbrahim Yıldız
• Ceyda Tunakan Dalgıç
• Hatice Özışık
• Melih Özışık
• Burçak Karaca
• Bülent Karabulut
• Rüçhan Uslu

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

• İrfan Cicin
• Mohammed Oukkal
• Hassen Mahfouf
• Amel Mezlini
• Blaha Larbaoui
• Slim Ben Ahmed
• Hassan Errihani
• Khalid Alsaleh
• Rhizlane Belbaraka
• Perran Fulden Yumuk
• Burce Goktas
• Mustafa Özgüroğlu

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival

• Juan Alors-Ruiz
• Salomé Sanz-Viedma
• Francisco Javier Fernández-Garcia
• Francisco Sendra-Portero

The Correlation of Magee Equations^TM and Oncotype DX^® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer

• Atilla Soran
• Kaori Tane
• Efe Sezgin
• Rohit Bhargava

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers

• Melek Ünçel
• Gülden Diniz
• Gamze Aköz
• Zübeyde Yıldırım Ekin
• Sevil Sayhan
• Serdar Yardım
• Semra Salimoğlu

Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy

• Hongxia Sun
• Hui Chen
• James Crespo
• Guilin Tang
• Melissa Robinson
• Bora Lim
• Ayşegül A. Şahin

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine

• İzzet Doğan
• Nail Paksoy
• Naziye Ak
• Sezai Vatansever
• Pınar Saip
• Adnan Aydıner

Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study

• Tülay Canda
• Ekrem Yavuz
• Necmettin Özdemir
• Sennur İlvan
• Serpil Sak Dizbay
• Merih Güray Durak
• Sıtkı Tuzlalı
• Osman Zekioğlu
• Atakan Demir
• Handan Onur
• Kasım Üstündağ
• Burçe Göktaş

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center

• Stephane Thibodeau
• Ioannis A. Voutsadakis

Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR

• Ramesh Omranipour
• Roghiyeh Jalili
• Adel Yazdankhahkenary
• Abdolali Assarian
• Mehrzad Mirzania
• Bita Eslami

Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study

• Damiano Gentile
• Andrea Sagona
• Ruggero Spoto
• Davide Franceschini
• Stefano Vaccari
• Valeriano Vinci
• Ersilia Biondi
• Lorenzo Scardina
• Corrado Tinterri

Case Report

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer

• Bülent Karagöz
• Alpaslan Özgün
• Levent Emirzeoğlu
• Tolga Tunçel
• Serkan Çelik
• Oğuz Bilgi
• Kemal Kara

RECURRENT SUPRAVENTRICULAR TACHYCARDIA ASSOCIATED WITH LAPATINIB: A CASE REPORT OF A PROBABLE CARDIAC ADVERSE EFFECT

• Özgür Tanrıverdi
• Nezih Meydan
• Sabri Barutca